[New Year's Message] Park Seong-su, CEO of Daewoong Pharmaceutical, "Expecting Best Ever Performance in 2024"

"Thanks to the Efforts of Employees Who Did Their Best"

Park Sung-soo, CEO of Daewoong Pharmaceutical, described 2024 as "a year that once again proved Daewoong Pharmaceutical's resilience" and stated that the company is expected to achieve its highest-ever performance in 2024.

Park Sung-soo, CEO of Daewoong Pharmaceutical. Daewoong Pharmaceutical

In his New Year's address on the 2nd, CEO Park said, "The excellent performance despite the uncertain economic environment was thanks to the efforts of employees who did their best in their respective positions."

Last year, Daewoong Pharmaceutical achieved its best results centered on three major innovative new drugs: Nabota, Pexuclu, and Enblo. The company also identified its first anticancer drug candidate, secured new pipelines such as obesity treatments, and continued innovation in formulation areas including microneedles and long-acting injectables.

Additionally, CEO Park presented five management policies for 2025: ▲Enhancing customer value ▲Fostering global talent ▲Becoming a global leader through innovative new drug development ▲Cultivating one global new drug with sales exceeding 1 trillion KRW ▲Focusing on digital new business development.

The first management policy, enhancing customer value, reflects the idea that Daewoong Pharmaceutical is no longer just a pharmaceutical company but must become a company that provides greater value to customers in the most effective way. Through the second policy, he urged all employees to grow into global talents who lead change and innovation.

Thirdly, he outlined a vision to expand the new drug pipeline in various fields such as gastrointestinal diseases, metabolic fibrosis, cancer, and autoimmune diseases to become a global leading company.

Regarding the fourth policy, CEO Park said, "The 'one product, 1 trillion KRW' goal goes beyond a simple sales target; it embodies our commitment to elevate the status of K-pharmaceutical bio globally and contribute to the healthy lives of people worldwide." He added, "We will achieve individual sales of 1 trillion KRW centered on the three major innovative new drugs: Nabota, Pexuclu, and Enblo."

Lastly, he mentioned the accelerated paradigm shift in the healthcare industry due to AI advancements and presented plans to build a comprehensive healthcare ecosystem based on data beyond drug-centered treatments and to nurture it as a new growth engine.

CEO Park then emphasized the importance of establishing a system where all employees can cooperate and grow together, stating, "All employees should 'brightly' make the core contents, standards, and success cases of the system easily understandable to everyone."

He also said, "We must build a convenient system by utilizing optimal tools to enable work in an efficient environment," and added, "Let us communicate 'transparently' so that all employees can work with a sense of ownership and find the best solutions."